23 completed, 9 active not recruiting, 9 terminated, 8 recruiting. 31 Phase 2, 28 Phase 1, 1 Phase 3.
Follow Recurrent Chronic Lymphocytic Leukemia: new trials by email Literature Review of Recurrent Chronic Lymphocytic Leukemia trials Research Report on Recurrent Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-05-27 | 2026-10-06 |
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-04-22 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial Acalabrutinib, Venetoclax, Biospecimen Collection - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2023-05-31 | 2026-10-23 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Ibrutinib, Ipilimumab, Nivolumab - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-07-14 | 2025-02-28 | |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Daratumumab, Ibrutinib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2020-11-11 | 2025-12-30 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Acalabrutinib, Obinutuzumab, Venetoclax - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 168 | 2020-07-29 | 2026-09-10 |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Duvelisib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 15 | 2020-05-13 | 2026-01-05 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 |
Showing 20 of 54. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (54) · Lymphoma, Mantle-Cell (19) · Lymphoma, Non-Hodgkin (17) · Lymphoma, Large B-Cell, Diffuse (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Hodgkin Disease (13) · Lymphoma, Follicular (13) · Multiple Myeloma (12) · Leukemia, Myeloid, Acute (11) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (10) · Lymphoma, B-Cell, Marginal Zone (10) · Leukemia, Prolymphocytic (9) · Myelodysplastic Syndromes (9) · Lymphoma, B-Cell (8) · Waldenstrom Macroglobulinemia (8)
Chronic Disease (54) · Disease Attributes (54) · Hemic and Lymphatic Diseases (54) · Immune System Diseases (54) · Immunoproliferative Disorders (54) · Leukemia, B-Cell (54) · Lymphatic Diseases (54) · Lymphoproliferative Disorders (54) · Neoplasms (54) · Neoplasms by Histologic Type (54) · Pathologic Processes (54) · Pathological Conditions, Signs and Symptoms (54) · Hematologic Diseases (53) · Leukemia (53) · Leukemia, Lymphoid (52)
Cyclophosphamide (16) · fludarabine phosphate (14) · ibrutinib (13) · Mycophenolic Acid (11) · Specimen Handling (10) · Biopsy (9) · Whole-Body Irradiation (9) · Cyclosporine (7) · Cyclosporins (7) · Magnetic Resonance Spectroscopy (7) · Lenalidomide (6) · Nivolumab (5) · Peripheral Blood Stem Cell Transplantation (5) · Rituximab (5) · fludarabine (5)
Fred Hutchinson Cancer Center (15) · M.D. Anderson Cancer Center (10) · Mayo Clinic (6) · National Cancer Institute (NCI) (5) · City of Hope Medical Center (4) · Jonsson Comprehensive Cancer Center (2) · OHSU Knight Cancer Institute (2) · Alexey Danilov, MD (1) · Emory University (1) · Joseph Tuscano (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Steven E. Coutre (1) · Sumithira Vasu (1) · University of Washington (1)
United States (53) · Denmark (2) · Germany (2) · Canada (1) · Italy (1)
Brenda Sandmaier (3) · Chitra Hosing (2) · David Maloney (2) · Mazyar Shadman (2) · Mohamed Sorror (2) · Nitin Jain (2) · Sumithira Vasu, MD (2) · Alessandra Ferrajoli (1) · Alexey Danilov (1) · Alexey V Danilov (1) · Amir A Toor, MD (1) · Asher Chanan-Khan (1) · Bhagirathbhai Dholaria, M.D. (1) · Craig Okada, M.D. (1) · Daniel A Pollyea (1)
PMID 32499241, PMID 34515338, PMID 39863139, PMID 27111235, PMID 27410923, PMID 28424162, PMID 29038338, PMID 30530801, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31141631, PMID 31177537, PMID 31248843, PMID 31648294, PMID 32478814, PMID 32603426, PMID 32967009, PMID 33720354, PMID 34110383, PMID 34196037, PMID 34492703, PMID 34666344, PMID 36287248, PMID 36631449, PMID 37774014, PMID 38836342, PMID 39333103, PMID 41043099, PMID 41678768, PMID 42389828
P30CA015704 (11), P01CA018029 (4), P30CA016672 (3), P01CA078902 (2), P30CA033572 (2), P30CA069533 (2), UM1CA186709 (2), 2015 (1), P30CA006516 (1), P30CA015083 (1), P30CA046934 (1), P30CA051008 (1), P30CA093373 (1), P50CA097274 (1), P50CA107399 (1)